Pharmacogenomics-based RNA interference nanodelivery: Focus on solid malignant tumors

Yitzhak Rosen, Urvashi M. Upadhyay, Noel M. Elman

Research output: Contribution to journalReview article

Abstract

Introduction: RNA interference represents one of the most promising strategies in fighting disease. However, small RNA interference faces substantial challenges for in vivo application due to the inherent instability of the RNA interference molecule. Among the nonviral gene delivery carriers, nanoparticles have attracted interest due to their success in various model systems. Nanomaterials have unique properties compared to conventional bulk materials that may be applicable in this setting. The nanoparticle complex carrying small interference RNA can undergo surface modification to achieve targeted modification for tissue-specific delivery. However, toxicity issues of the delivery systems need to be addressed and they require a pharmacogenomic profile of their own. Areas covered: The authors review pharmacogenomics, toxicogenomics, nanoparticle-based drug delivery, and small interference RNA, with a focus on how logically engineered nanoparticle delivery systems can be used for personalized medicine in malignant tumors. Expert opinion: Pharmacogenomics may be helpful in addressing possible individualized drug response for both the gene silencing capability of the delivered siRNA and the nanoparticle drug delivery system as both complete and distinct units. This may be done by assessing variations in gene expressions and single nucleotide polymorphisms. Patient profiling may be key as patient noncompliance due to toxicity plays a major role in treatment failure.

Original languageEnglish (US)
Pages (from-to)755-766
Number of pages12
JournalExpert Opinion on Drug Delivery
Volume9
Issue number7
DOIs
StatePublished - Jul 1 2012
Externally publishedYes

Fingerprint

Pharmacogenetics
RNA Interference
Nanoparticles
Neoplasms
Toxicogenetics
Precision Medicine
Nanostructures
Expert Testimony
Gene Silencing
Drug Delivery Systems
Patient Compliance
Treatment Failure
Pharmaceutical Preparations
Small Interfering RNA
Single Nucleotide Polymorphism
Gene Expression
Genes

Keywords

  • delivery
  • functionalization
  • nanoparticle
  • pharmacogenomics
  • targeted

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Pharmacogenomics-based RNA interference nanodelivery : Focus on solid malignant tumors. / Rosen, Yitzhak; Upadhyay, Urvashi M.; Elman, Noel M.

In: Expert Opinion on Drug Delivery, Vol. 9, No. 7, 01.07.2012, p. 755-766.

Research output: Contribution to journalReview article

@article{04f6f058e77346f4b6b07be09ca66dbd,
title = "Pharmacogenomics-based RNA interference nanodelivery: Focus on solid malignant tumors",
abstract = "Introduction: RNA interference represents one of the most promising strategies in fighting disease. However, small RNA interference faces substantial challenges for in vivo application due to the inherent instability of the RNA interference molecule. Among the nonviral gene delivery carriers, nanoparticles have attracted interest due to their success in various model systems. Nanomaterials have unique properties compared to conventional bulk materials that may be applicable in this setting. The nanoparticle complex carrying small interference RNA can undergo surface modification to achieve targeted modification for tissue-specific delivery. However, toxicity issues of the delivery systems need to be addressed and they require a pharmacogenomic profile of their own. Areas covered: The authors review pharmacogenomics, toxicogenomics, nanoparticle-based drug delivery, and small interference RNA, with a focus on how logically engineered nanoparticle delivery systems can be used for personalized medicine in malignant tumors. Expert opinion: Pharmacogenomics may be helpful in addressing possible individualized drug response for both the gene silencing capability of the delivered siRNA and the nanoparticle drug delivery system as both complete and distinct units. This may be done by assessing variations in gene expressions and single nucleotide polymorphisms. Patient profiling may be key as patient noncompliance due to toxicity plays a major role in treatment failure.",
keywords = "delivery, functionalization, nanoparticle, pharmacogenomics, targeted",
author = "Yitzhak Rosen and Upadhyay, {Urvashi M.} and Elman, {Noel M.}",
year = "2012",
month = "7",
day = "1",
doi = "10.1517/17425247.2012.685932",
language = "English (US)",
volume = "9",
pages = "755--766",
journal = "Expert Opinion on Drug Delivery",
issn = "1742-5247",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Pharmacogenomics-based RNA interference nanodelivery

T2 - Focus on solid malignant tumors

AU - Rosen, Yitzhak

AU - Upadhyay, Urvashi M.

AU - Elman, Noel M.

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Introduction: RNA interference represents one of the most promising strategies in fighting disease. However, small RNA interference faces substantial challenges for in vivo application due to the inherent instability of the RNA interference molecule. Among the nonviral gene delivery carriers, nanoparticles have attracted interest due to their success in various model systems. Nanomaterials have unique properties compared to conventional bulk materials that may be applicable in this setting. The nanoparticle complex carrying small interference RNA can undergo surface modification to achieve targeted modification for tissue-specific delivery. However, toxicity issues of the delivery systems need to be addressed and they require a pharmacogenomic profile of their own. Areas covered: The authors review pharmacogenomics, toxicogenomics, nanoparticle-based drug delivery, and small interference RNA, with a focus on how logically engineered nanoparticle delivery systems can be used for personalized medicine in malignant tumors. Expert opinion: Pharmacogenomics may be helpful in addressing possible individualized drug response for both the gene silencing capability of the delivered siRNA and the nanoparticle drug delivery system as both complete and distinct units. This may be done by assessing variations in gene expressions and single nucleotide polymorphisms. Patient profiling may be key as patient noncompliance due to toxicity plays a major role in treatment failure.

AB - Introduction: RNA interference represents one of the most promising strategies in fighting disease. However, small RNA interference faces substantial challenges for in vivo application due to the inherent instability of the RNA interference molecule. Among the nonviral gene delivery carriers, nanoparticles have attracted interest due to their success in various model systems. Nanomaterials have unique properties compared to conventional bulk materials that may be applicable in this setting. The nanoparticle complex carrying small interference RNA can undergo surface modification to achieve targeted modification for tissue-specific delivery. However, toxicity issues of the delivery systems need to be addressed and they require a pharmacogenomic profile of their own. Areas covered: The authors review pharmacogenomics, toxicogenomics, nanoparticle-based drug delivery, and small interference RNA, with a focus on how logically engineered nanoparticle delivery systems can be used for personalized medicine in malignant tumors. Expert opinion: Pharmacogenomics may be helpful in addressing possible individualized drug response for both the gene silencing capability of the delivered siRNA and the nanoparticle drug delivery system as both complete and distinct units. This may be done by assessing variations in gene expressions and single nucleotide polymorphisms. Patient profiling may be key as patient noncompliance due to toxicity plays a major role in treatment failure.

KW - delivery

KW - functionalization

KW - nanoparticle

KW - pharmacogenomics

KW - targeted

UR - http://www.scopus.com/inward/record.url?scp=84862737704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862737704&partnerID=8YFLogxK

U2 - 10.1517/17425247.2012.685932

DO - 10.1517/17425247.2012.685932

M3 - Review article

C2 - 22658087

AN - SCOPUS:84862737704

VL - 9

SP - 755

EP - 766

JO - Expert Opinion on Drug Delivery

JF - Expert Opinion on Drug Delivery

SN - 1742-5247

IS - 7

ER -